1.S-propargyl-cysteine delays the progression of atherosclerosis and increases eNOS phosphorylation in endothelial cells.
Zhi-Ming LI ; Ping LI ; Lei ZHU ; Yu-Wen ZHANG ; Yi-Chun ZHU ; He WANG ; Bo YU ; Ming-Jie WANG
Acta Physiologica Sinica 2023;75(3):317-327
		                        		
		                        			
		                        			The present study aimed to investigate the protective effect of S-propargyl-cysteine (SPRC) on atherosclerosis progression in mice. A mouse model of vulnerable atherosclerotic plaque was created in ApoE-/- mice by carotid artery tandem stenosis (TS) combined with a Western diet. Macrophotography, lipid profiles, and inflammatory markers were measured to evaluate the antiatherosclerotic effects of SPRC compared to atorvastatin as a control. Histopathological analysis was performed to assess the plaque stability. To explore the protective mechanism of SPRC, human umbilical vein endothelial cells (HUVECs) were cultured in vitro and challenged with oxidized low-density lipoprotein (ox-LDL). Cell viability was determined with a Cell Counting Kit-8 (CCK-8). Endothelial nitric oxide synthase (eNOS) phosphorylation and mRNA expression were detected by Western blot and RT-qPCR respectively. The results showed that the lesion area quantified by en face photographs of the aortic arch and carotid artery was significantly less, plasma total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were reduced, plaque collagen content was increased and matrix metalloproteinase-9 (MMP-9) was decreased in 80 mg/kg per day SPRC-treated mice compared with model mice. These findings support the role of SPRC in plaque stabilization. In vitro studies revealed that 100 μmol/L SPRC increased the cell viability and the phosphorylation level of eNOS after ox-LDL challenge. These results suggest that SPRC delays the progression of atherosclerosis and enhances plaque stability. The protective effect may be at least partially related to the increased phosphorylation of eNOS in endothelial cells.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Atherosclerosis
		                        			;
		                        		
		                        			Cholesterol/metabolism*
		                        			;
		                        		
		                        			Cysteine/pharmacology*
		                        			;
		                        		
		                        			Human Umbilical Vein Endothelial Cells/metabolism*
		                        			;
		                        		
		                        			Lipoproteins, LDL/pharmacology*
		                        			;
		                        		
		                        			Nitric Oxide Synthase Type III/metabolism*
		                        			;
		                        		
		                        			Phosphorylation
		                        			;
		                        		
		                        			Plaque, Atherosclerotic/pathology*
		                        			
		                        		
		                        	
2.Associations between various lipid components and premature myocardial infarction: a cross-sectional study.
Jing SHI ; Hai Yu ZHANG ; Ding Yu WANG ; Qiang GAO ; Li SHENG ; Peng Wei SONG ; Yu ZHANG ; Yue LI
Chinese Journal of Cardiology 2023;51(3):278-287
		                        		
		                        			
		                        			Objective: Hyperlipidemia is closely related to premature acute myocardial infarction (AMI). The present study was performed to explore the correlation between various blood lipid components and the risk of premature AMI. Methods: This is a cross-sectional retrospective study. Consecutive patients with acute ST-segment elevation myocardial infarction (STEMI), who completed coronary angiography from October 1, 2020 to September 30, 2022 in our hospital, were enrolled and divided into premature AMI group (male<55 years old, female<65 years old) and late-onset AMI group. Total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), non-HDL-C, lipoprotein (a) (Lp (a)), apolipoprotein B (ApoB), apolipoprotein A-1 (ApoA-1), non-HDL-C/HDL-C and ApoB/ApoA-1 were analyzed. The correlation between the above blood lipid indexes and premature AMI was analyzed and compared by logistic regression, restricted cubic spline and receiver operating characteristic curve (ROC). Results: A total of 1 626 patients with STEMI were enrolled in this study, including 409 patients with premature AMI and 1 217 patients with late-onset AMI. Logistic regression analysis showed that the risk of premature AMI increased significantly with the increase of TG, non-HDL-C/HDL-C, non-HDL-C, ApoB/ApoA-1, TC and ApoB quintiles; while LDL-C, ApoA-1 and Lp (a) had no significant correlation with premature AMI. The restricted cubic spline graph showed that except Lp (a), LDL-C, ApoA-1 and ApoB/ApoA-1, other blood lipid indicators were significantly correlated with premature AMI. The ROC curve showed that TG and non-HDL-C/HDL-C had better predictive value for premature AMI. Inconsistency analysis found that the incidence and risk of premature AMI were the highest in patients with high TG and high non-HDL-C/HDL-C. Conclusion: TG, non-HDL-C/HDL-C and other blood lipid indexes are significantly increased in patients with premature AMI, among which TG is the parameter, most closely related to premature AMI, and future studies are needed to explore the impact of controlling TG on incidence of premature AMI.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Cross-Sectional Studies
		                        			;
		                        		
		                        			Cholesterol, LDL
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			ST Elevation Myocardial Infarction
		                        			;
		                        		
		                        			Apolipoprotein A-I
		                        			;
		                        		
		                        			Myocardial Infarction
		                        			;
		                        		
		                        			Cholesterol
		                        			;
		                        		
		                        			Apolipoproteins B
		                        			;
		                        		
		                        			Triglycerides
		                        			;
		                        		
		                        			Cholesterol, HDL
		                        			;
		                        		
		                        			Lipids
		                        			;
		                        		
		                        			Lipoproteins
		                        			
		                        		
		                        	
3.Research progress in targeting autophagy of traditional Chinese medicine and natural compounds to regulate atherosclerosis.
Man-Li ZHOU ; Yun-Feng YU ; Yan-Zhen ZHAO ; Xiao-Xin LUO ; Jia-le ZHU ; Yi-Lei HU ; Wei-Xiong JIAN
China Journal of Chinese Materia Medica 2023;48(2):311-320
		                        		
		                        			
		                        			Atherosclerosis(AS) is the common pathological basis of many ischemic cardiovascular diseases, and its formation process involves various aspects such as vascular endothelial injury and platelet activation. Vascular endothelial injury is the initiating factor of AS plaque. Monocytes are recruited to differentiate into macrophages at the damaged endothelial cells, which absorb oxidized low-density lipoprotein(ox-LDL) and slowly transform into foam cells. Smooth muscle cells(SMCs) proliferate and migrate continuously. As the only cell producing interstitial collagen fibers in the fibrous cap, SMCs largely determine whether the plaque ruptured or not. The amplifying inflammatory response during the formation of AS recruits platelets to adhere to the damaged area of vascular endothelium and stimulates excessive platelet aggregation. Autophagy activity is associated with vascular lesions and abnormal platelet activation, and excessive autophagy is considered to be a negative factor for plaque stability. Therefore, precise regulation of different types of vascular autophagy and platelet autophagy to treat AS may provide a new therapeutic perspective for the prevention and treatment of atherosclerotic ischemic cardiovascular disease. Currently, treatment strategies for AS still focus on lowering lipid levels with high-intensity statins, which often cause significant side effects. Therefore, the development of safer and more effective drugs and treatment modes is the focus of current research. Traditional Chinese medicine and natural compounds have the potential to treat AS by targeted autophagy, and have been playing an increasingly important role in the prevention and treatment of cardiovascular diseases in China. This paper summarizes the experimental studies on different vascular cell types and platelet autophagy in AS, and sums up the published research results on targeted autophagy of traditional Chinese medicine and natural plant compounds to regulate AS, providing new ideas for further research.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Endothelial Cells/metabolism*
		                        			;
		                        		
		                        			Cardiovascular Diseases
		                        			;
		                        		
		                        			Medicine, Chinese Traditional
		                        			;
		                        		
		                        			Atherosclerosis/prevention & control*
		                        			;
		                        		
		                        			Lipoproteins, LDL/metabolism*
		                        			;
		                        		
		                        			Endothelium, Vascular
		                        			;
		                        		
		                        			Plaque, Atherosclerotic
		                        			;
		                        		
		                        			Autophagy
		                        			
		                        		
		                        	
4.LOX-1 Regulation in Anti-atherosclerosis of Active Compounds of Herbal Medicine: Current Knowledge and the New Insight.
Si-Jie YAO ; Tao-Hua LAN ; Xin-Yu ZHANG ; Qiao-Huang ZENG ; Wen-Jing XU ; Xiao-Qing LI ; Gui-Bao HUANG ; Tong LIU ; Wei-Hui LYU ; Wei JIANG
Chinese journal of integrative medicine 2023;29(2):179-185
		                        		
		                        			
		                        			Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) have recently been identified to be closely related to the occurrence and development of atherosclerosis (AS). A growing body of evidence has suggested Chinese medicine takes unique advantages in preventing and treating AS. In this review, the related research progress of AS and LOX-1 has been summarized. And the anti-AS effects of 10 active components of herbal medicine through LOX-1 regulation have been further reviewed. As a potential biomarker and target for intervention in AS, LOX-1 targeted therapy might provide a promising and novel approach to atherosclerotic prevention and treatment.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Atherosclerosis
		                        			;
		                        		
		                        			Scavenger Receptors, Class E/physiology*
		                        			;
		                        		
		                        			Biomarkers
		                        			;
		                        		
		                        			Plant Extracts
		                        			;
		                        		
		                        			Lipoproteins, LDL
		                        			
		                        		
		                        	
5.Possible Risk Factors for Bone Marrow Fibroplasia in Patients with Polycythemia Vera.
De-Hao WANG ; Pei ZHAO ; Zi-Qing WANG ; Er-Peng YANG ; Yu-Meng LI ; Ji-Cong NIU ; Yi CHEN ; Ke CHEN ; Ming-Jing WANG ; Wei-Yi LIU ; Yan LYU ; Xiao-Mei HU
Journal of Experimental Hematology 2023;31(6):1780-1786
		                        		
		                        			OBJECTIVE:
		                        			To understand the biological characteristics of polycythemia vera (PV) patients with myeloid fibroplasia, and further analyze the risk factors affecting myeloid fibroplasia in PV patients, so as to provide ideas for predicting the occurrence of myeloid fibroplasia in PV patients.
		                        		
		                        			METHODS:
		                        			Forty patients with PV in the Department of Hematology, Xiyuan Hospital of China Academy of Chinese Medical Sciences were collected and divided into two groups, with (hyperplasia group) and without (Non-proliferative group) hyperplasia of bone marrow fibers. The differences of basic clinical characteristics, blood routine, biochemistry, bone marrow cells, coagulation function and other indicators between the two groups were compared, and the independent risk factors affecting the proliferation of bone marrow fibrous tissue in PV patients were further analyzed by multivariate regression.
		                        		
		                        			RESULTS:
		                        			Compared with Non-proliferative group, the JAK2 mutation rate (95% vs 70%,P=0.037), eosinophilic cell count (0.19 vs 0.11, P=0.047) and eosinophilic percentage (1.84 vs 1.27, P=0.001) in PV patients with hyperplasia were significantly increased, triglycerides (1.55 vs 1.91, P=0.038) and low-density lipoprotein (1.50 vs 3.08, P=0.000) were significantly reduced, bone marrow hematopoietic volume (0.85 vs 0.6, P=0.001), granulocyte/erythrocyte ratio (3.40 vs 1.89, P=0.033), lymphocyte/erythrocyte ratio (0.60 vs 0.42, P=0.033), and granulocyte+lymphocyte/erythrocyte ratio (3.72 vs 2.37, P=0.026) were significantly increased, thrombin time (18.84 vs 18.12, P=0.043) was significantly prolonged. Multivariate regression analysis results showed that peripheral blood eosinophil ≥2% and low-density lipoprotein ≤2 mmol/L were independent risk factors for bone marrow fibrous tissue hyperplasia in PV patients (P<0.05).
		                        		
		                        			CONCLUSION
		                        			Increased proportion of peripheral blood eosinophils and decreased low density lipoprotein are risk factors for bone marrow fibrous tissue hyperplasia in PV patients.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Bone Marrow/pathology*
		                        			;
		                        		
		                        			Polycythemia Vera
		                        			;
		                        		
		                        			Hyperplasia/pathology*
		                        			;
		                        		
		                        			Granulocytes/pathology*
		                        			;
		                        		
		                        			Janus Kinase 2/genetics*
		                        			;
		                        		
		                        			Risk Factors
		                        			;
		                        		
		                        			Lipoproteins, LDL
		                        			;
		                        		
		                        			Polycythemia/pathology*
		                        			
		                        		
		                        	
6.miR-509-3p promotes oxidized low-density lipoprotein-induced apoptosis in mouse aortic endothelial cells.
Rui ZHANG ; Yanqiu SONG ; Fumei ZHAO ; Ting LIU ; Hongliang CONG ; Hui ZHAO
Chinese Critical Care Medicine 2023;35(12):1291-1297
		                        		
		                        			OBJECTIVE:
		                        			To investigate the effect of microRNA-509-3p (miR-509-3p) on the apoptosis of atherosclerotic vascular endothelial cells.
		                        		
		                        			METHODS:
		                        			Mouse aortic endothelial cells (MAECs) were divided into normal control group, oxidized low-density lipoprotein (ox-LDL) group, miR-509-3p overexpression group, miR-509-3p overexpression control group, miR-509-3p inhibitor + ox-LDL group, and miR-509-3p inhibitor control + ox-LDL group. MAEC were induced with 100 mg/L ox-LDL for 24 hours, and then transfected with miR-509-3p overexpression/inhibitor and corresponding control for 48 hours. The miR-509-3p expression in MAECs exposed to ox-LDL was detected using real-time fluorescence quantitative polymerase chain reaction (RT-qPCR). Flow cytometry was used to detect the level of apoptosis, and cell counting kit (CCK-8) was used to detect the proliferation activity of MAECs. The direct gene targets of miR-509-3p were predicted using bioinformatics analyses and confirmed using a dual luciferase reporter assay. The expression of Bcl-2 mRNA and protein was detected by RT-qPCR and Western blotting, respectively.
		                        		
		                        			RESULTS:
		                        			Compared with the normal control group, miR-509-3p was significantly upregulated in ox-LDL-stimulated MAECs (1.68±0.85 vs. 1.00±0.30, t = 2.398, P < 0.05). After transfection of MAECs with miR-509-3p overexpression, the luciferase activity of the BCL2 3'UTR WT reporter gene was significantly lower than that of miR-509-3p overexpression control group (0.83±0.06 vs. 1.00±0.07, t = 4.531, P = 0.001). The luciferase activity of the BCL2 3'-UTR mutant (MUT) reporter gene was not significantly different from that of miR-509-3p overexpression control group (0.94±0.05 vs. 1.00±0.08, t = 1.414, P = 0.188). Compared with the normal control group and miR-509-3p mimics control group, the cell proliferation activity was decreased [(0.60±0.06)% vs. (1.00±0.09)%, (0.89±0.04)%, both P < 0.01], the percentage of apoptotic cells were increased [(23.46±2.02)% vs. (7.66±1.52)%, (10.40±0.78)%, both P < 0.05], and the mRNA and protein expression of Bcl-2 were significantly downregulated (Bcl-2 mRNA: 0.52±0.13 vs. 1.00±0.36, 1.10±0.19, Bcl-2 protein: 0.42±0.07 vs. 1.00±0.11, 0.93±0.10, both P < 0.01) in miR-509-3p overexpression group. Compared with the ox-LDL group, inhibition of miR-509-3p expression could increase the proliferation activity of MAECs induced by ox-LDL [(0.64±0.35)% vs. (0.34±0.20%)%, P < 0.05], and reduce the apoptosis rate [(13.59±2.22)% vs. (29.84±5.19)%, P < 0.01], and up-regulated the expression of Bcl-2 mRNA and protein in MAECs induced by ox-LDL (Bcl-2 mRNA relative expression: 0.82±0.09 vs. 0.52±0.10, Bcl-2 protein relative expression: 0.83±0.17 vs. 0.40±0.07, both P < 0.05).
		                        		
		                        			CONCLUSIONS
		                        			Bcl-2 was one of the target genes of miR-509-3p. miR-509-3p can reduce the proliferation activity of endothelial cells, reduce the expression of Bcl-2, and promote cell apoptosis, thereby promoting the occurrence and development of atherosclerosis. Inhibition of miR-509-3p expression may be a potential therapeutic target for atherosclerosis.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Endothelial Cells
		                        			;
		                        		
		                        			MicroRNAs/metabolism*
		                        			;
		                        		
		                        			Signal Transduction
		                        			;
		                        		
		                        			Lipoproteins, LDL/metabolism*
		                        			;
		                        		
		                        			Apoptosis
		                        			;
		                        		
		                        			RNA, Messenger/metabolism*
		                        			;
		                        		
		                        			Proto-Oncogene Proteins c-bcl-2/pharmacology*
		                        			;
		                        		
		                        			Atherosclerosis/metabolism*
		                        			;
		                        		
		                        			Luciferases/pharmacology*
		                        			;
		                        		
		                        			Cell Proliferation
		                        			;
		                        		
		                        			Human Umbilical Vein Endothelial Cells
		                        			
		                        		
		                        	
7.Zuogui Jiangtang Qinggan Formula improves glucolipid metabolism in type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease by regulating FoxO1/MTP/APOB signaling pathway.
Yi-Xin XIANG ; Ya-Lan HUANG ; Min ZHOU ; Jun-Ju ZOU ; Xiu LIU ; Zi-Yu LIU ; Fan XIAO ; Rong YU ; Qin XIANG
China Journal of Chinese Materia Medica 2023;48(16):4438-4445
		                        		
		                        			
		                        			This study aimed to investigate the effect and mechanism of Zuogui Jiangtang Qinggan Formula(ZGJTQG) on the glucolipid metabolism of type 2 diabetes mellitus(T2DM) complicated with non-alcoholic fatty liver disease(NAFLD). NAFLD was induced by a high-fat diet(HFD) in MKR mice(T2DM mice), and a model of T2DM combined with NAFLD was established. Forty mice were randomly divided into a model group, a metformin group(0.067 g·kg~(-1)), and high-and low-dose ZGJTQG groups(29.64 and 14.82 g·kg~(-1)), with 10 mice in each group. Ten FVB mice of the same age were assigned to the normal group. Serum and liver tissue specimens were collected from mice except for those in the normal and model groups after four weeks of drug administration by gavage, and fasting blood glucose(FBG) and fasting insulin(FINS) levels were measured. The levels of total cholesterol(TC), triglyceride(TG), and low-density lipoprotein(LDL) were detected by the single reagent GPO-PAP method. Very low-density lipoprotein(VLDL) was detected by enzyme-linked immunosorbent assay(ELISA). Alanine aminotransferase(ALT) and aspartate ami-notransferase(AST) were determined by the Reitman-Frankel assay. The pathological changes in the liver were observed by hematoxylin-eosin(HE) staining and oil red O staining. Real-time fluorescence-based quantitative polymerase chain reaction(real-time PCR) and Western blot were adopted to detect the mRNA and protein expression of forkhead transcription factor O1(FoxO1), microsomal triglyceride transfer protein(MTP), and apolipoprotein B(APOB) in the liver. The results showed that high-dose ZGJTQG could signi-ficantly reduce the FBG and FINS levels(P<0.05, P<0.01), improve glucose tolerance and insulin resistance(P<0.05, P<0.01), alleviate the liver damage caused by HFD which was reflected in improving liver steatosis, and reduce the serum levels of TC, TG, LDL, VLDL, ALT, and AST(P<0.05, P<0.01) in T2DM mice combined with NAFLD. The findings also revealed that the mRNA and protein expression of FoxO1, MTP, and APOB in the liver was significantly down-regulated after the intervention of high-dose ZGJTQG(P<0.05, P<0.01). The above study showed that ZGJTQG could effectively improve glucolipid metabolism in T2DM combined with NAFLD, and the mechanism was closely related to the regulation of the FoxO1/MTP/APOB signaling pathway.
		                        		
		                        		
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Non-alcoholic Fatty Liver Disease/metabolism*
		                        			;
		                        		
		                        			Diabetes Mellitus, Type 2/metabolism*
		                        			;
		                        		
		                        			Liver
		                        			;
		                        		
		                        			Lipoproteins, LDL/metabolism*
		                        			;
		                        		
		                        			Signal Transduction
		                        			;
		                        		
		                        			Diet, High-Fat/adverse effects*
		                        			;
		                        		
		                        			RNA, Messenger/metabolism*
		                        			
		                        		
		                        	
8.Advances in diagnosis and treatment of familial hypercholesterolemia.
Hua ZHENG ; Si Jie JIANG ; Li Long LIN
Journal of Southern Medical University 2023;43(1):153-156
		                        		
		                        			
		                        			Familial hypercholesterolemia (FH) is an autosomal dominant inherited disease caused by abnormal lipoprotein metabolism. Patients with FH have a significantly increased risk of coronary artery disease (CAD) due to long-term exposure to high levels of low-density lipoprotein (LDL). The diagnosis of FH relies heavily on gene detection, and examination of LDL receptor (LDLR) function is of great significance in its treatment. This review summarizes the current advances in the screening, diagnosis, and treatment of FH and functional analysis of LDLR gene mutations.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hyperlipoproteinemia Type II/therapy*
		                        			;
		                        		
		                        			Coronary Artery Disease
		                        			;
		                        		
		                        			Lipoproteins, LDL
		                        			;
		                        		
		                        			Mutation
		                        			
		                        		
		                        	
9.Clinical significance of oxidized low-density lipoprotein antibody in antiphospholipid syndrome.
Yu Ke HOU ; Qing Meng CAI ; Xiang Jun LIU ; Ze Lin YUN ; Chun LI ; Xue Wu ZHANG
Journal of Peking University(Health Sciences) 2022;54(6):1117-1122
		                        		
		                        			OBJECTIVE:
		                        			To investigate the significance and distribution of oxidized low-density lipoprotein antibodies (ox-LDL-Ab) in patients with antiphospholipid syndrome (APS).
		                        		
		                        			METHODS:
		                        			In this study, 334 patients who were hospitalized in the Department of Rheumatology and Immunology, Peking University People's Hospital were included. There were 162 APS patients, 122 patients with other autoimmune diseases without thrombosis or obstetric disease as disease control and 50 healthy controls. The clinical data and laboratory indicators were retrospectively collected. The ox-LDL-Ab, anticardiolipin (aCL) IgG/IgA/IgM, and anti-β2-glycoprotein Ⅰ (aβ2GPI) IgG/IgA/IgM were detected by enzyme-linked immunosorbent assay (ELISA). The relationship between ox-LDL-Ab and clinical and laboratory parameters were analyzed by SPSS 27.0.
		                        		
		                        			RESULTS:
		                        			In APS group, 60.5% of patients had thrombosis, 48.1% had pregnancy morbidity, 34.0% had thrombocytopenia. The positive rates of aCL, aβ2GPI and lupus anticoagulant (LAC) were 17.9%, 34.6%, and 46.9%, respectively. The ox-LDL-Ab titers and positive rate in APS group were higher than that in healthy controls [titers: 40.8 (25.4-66.0) U/mL vs. 24.1 (12.3-36.5) U/mL, P=0.001; positive rate: 67.3% vs. 36.0%, P=0.001]. The diffe-rences in titers and positive rate of ox-LDL-Ab between APS patients and disease controls were not statistically significant [titers: 40.8 (25.4-66.0) U/mL vs. 35.9 (24.2-53.1) U/mL, P=0.118; positive rate: 67.3% vs. 61.5%, P=0.318]. The area under curve (AUC) for aβ2GPI, aCL, and ox-LDL-Ab were 0.745 (95%CI: 0.692-0.797), 0.666 (95%CI: 0.608-0.724), 0.609 (95%CI: 0.549-0.669), respectively. The Youden's index was 0.388, 0.269, and 0.132, respectively. The AUC for ox-LDL-Ab in seronegative APS patients was 0.562 (95%CI: 0.480-0.645). The sensitivity and specificity of ox-LDL-Ab in seronegative APS patients were 63.9% and 47.0%, respectively, and the Youden's index was 0.109. The ox-LDL-Ab positive group had higher positive rate of aβ2GPI (42.2% vs. 18.9%, P=0.003) and aCL (22.9% vs. 7.5%, P=0.017) than the ox-LDL-Ab negative group. There was no correlation between ox-LDL-Ab and thrombosis, coronary artery disease, pregnancy morbidity, hyperlipidemia, hypocomplementemia, and LAC positivity.
		                        		
		                        			CONCLUSION
		                        			Ox-LDL-Ab was correlated with aCL and aβ2GPI, and no association were observed between ox-LDL-Ab and thrombosis, coronary artery disease, and pregnancy morbidity.
		                        		
		                        		
		                        		
		                        			Pregnancy
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Antiphospholipid Syndrome
		                        			;
		                        		
		                        			Antibodies, Anticardiolipin
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Coronary Artery Disease
		                        			;
		                        		
		                        			Clinical Relevance
		                        			;
		                        		
		                        			beta 2-Glycoprotein I
		                        			;
		                        		
		                        			Lupus Coagulation Inhibitor
		                        			;
		                        		
		                        			Lipoproteins, LDL
		                        			;
		                        		
		                        			Autoantibodies
		                        			;
		                        		
		                        			Immunoglobulin G
		                        			;
		                        		
		                        			Immunoglobulin A
		                        			;
		                        		
		                        			Thrombosis
		                        			;
		                        		
		                        			Immunoglobulin M
		                        			
		                        		
		                        	
10.Components and lipid-lowering effect of total saponins from underground part of Gynostemma pentaphyllum.
Fei TENG ; Xiang-Wei LI ; Min LI ; Dong-Dong FAN ; Jing-Jing ZHU ; Hui-Min GAO ; Zhi-Min WANG
China Journal of Chinese Materia Medica 2022;47(18):5022-5031
		                        		
		                        			
		                        			The saponins in different parts of Gynostemma pentaphyllum were analyzed via UPLC-Q-TOF-MS~E. A total of 46 saponins were identified, and the underground part had 26 saponins more than the aboveground part, most of which were trisaccharide saponins. The rat model of hyperlipidemia was established with high-fat diet. This study explored the lipid-lowering activity of total saponins in the underground part of G. pentaphyllum, so as to provide a theoretical basis for the comprehensive utilization of the underground part of G. pentaphyllum. A total of 99 healthy SD rats were randomly assigned into a blank group, a model group, a positive drug group, an aboveground total saponins group, and low-, medium-, and high-dose underground total saponins groups. Except the blank group, the other groups were fed with high-fat diet for 6 weeks. Then, the blood was collected from the orbital cavity to determine whether the modeling was successful according to the serum levels of total cholesterol(TC) and triglyceride(TG). After intragastric administration of the corresponding agents for 30 continuous days, the physical state of the rats were observed, and the body weight and liver specific gravity were measured. Furthermore, the levels of TC, TG, low-density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol(HDL-C), alanine transaminase(ALT), aspartate transaminase(AST), bilirubin, and total bile acids in serum, as well as the levels of superoxide dismutase(SOD), malondialdehyde(MDA), peroxidase proliferator-activated receptor(PPAR-γ) in the liver tissue, were determined. The pathological changes of liver was observed via HE staining. The results showed that the aboveground total saponins and medium-and high-dose underground total saponins can treat hepatocyte steatosis, lower TC, TG, LDL-C, ALT, AST, total bilirubin, MDA, and PPAR-γ levels, and increase HDL-C and SOD levels in the model rats. The effect tended to be more obvious with the increase in dosage. Therefore, the total saponins in the underground part of G. pentaphyllum have good pharmacological effect of reducing blood lipid, which provides a theoretical basis for the comprehensive utilization of the underground part of G. pentaphyllum.
		                        		
		                        		
		                        		
		                        			Alanine Transaminase/analysis*
		                        			;
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Aspartate Aminotransferases/analysis*
		                        			;
		                        		
		                        			Bile Acids and Salts/blood*
		                        			;
		                        		
		                        			Bilirubin/blood*
		                        			;
		                        		
		                        			Cholesterol, LDL/blood*
		                        			;
		                        		
		                        			Diet, High-Fat/adverse effects*
		                        			;
		                        		
		                        			Gynostemma/chemistry*
		                        			;
		                        		
		                        			Hypolipidemic Agents/therapeutic use*
		                        			;
		                        		
		                        			Lipoproteins, HDL/blood*
		                        			;
		                        		
		                        			Liver/metabolism*
		                        			;
		                        		
		                        			Malondialdehyde/analysis*
		                        			;
		                        		
		                        			Peroxisome Proliferator-Activated Receptors/analysis*
		                        			;
		                        		
		                        			Rats
		                        			;
		                        		
		                        			Rats, Sprague-Dawley
		                        			;
		                        		
		                        			Saponins/therapeutic use*
		                        			;
		                        		
		                        			Superoxide Dismutase
		                        			;
		                        		
		                        			Triglycerides/blood*
		                        			;
		                        		
		                        			Trisaccharides/therapeutic use*
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail